An Alzheimer’s First

A new drug called aducanumab might become the first therapy approved to slow the progression of Alzheimer’s disease, helping sufferers preserve their memory longer. Aducanumab targets a protein called amyloid, which scientists think may cause Alzheimer’s. After discontinuing trials of the drug in March 2019 because of disappointing results, Biogen announced that a new analysis of the data indicated that those with mild, early Alzheimer’s did indeed benefit and that it planned to restart trials in 2020.